ZA201002035B - Use of gestagens in combination with (6s)-5-methyletrahydrofolate for the thepary of endometriosis with simultaneous reduction of therapy side effects and the reduction of the risk of congenital malformations in case of pregnancy - Google Patents

Use of gestagens in combination with (6s)-5-methyletrahydrofolate for the thepary of endometriosis with simultaneous reduction of therapy side effects and the reduction of the risk of congenital malformations in case of pregnancy

Info

Publication number
ZA201002035B
ZA201002035B ZA2010/02035A ZA201002035A ZA201002035B ZA 201002035 B ZA201002035 B ZA 201002035B ZA 2010/02035 A ZA2010/02035 A ZA 2010/02035A ZA 201002035 A ZA201002035 A ZA 201002035A ZA 201002035 B ZA201002035 B ZA 201002035B
Authority
ZA
South Africa
Prior art keywords
reduction
thepary
methyletrahydrofolate
gestagens
endometriosis
Prior art date
Application number
ZA2010/02035A
Inventor
Christian Seitz
Annemarie Wasswefall
Konstanze Diefenbach
Kristina King
Holger Zimmermann
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38846909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201002035(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of ZA201002035B publication Critical patent/ZA201002035B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA2010/02035A 2007-08-24 2010-03-23 Use of gestagens in combination with (6s)-5-methyletrahydrofolate for the thepary of endometriosis with simultaneous reduction of therapy side effects and the reduction of the risk of congenital malformations in case of pregnancy ZA201002035B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07016642A EP2027855A1 (en) 2007-08-24 2007-08-24 Use of gestagens in combination with (6S)5-methyl tetrahydro folate for endometriosis therapy with simultaneous reduction of the side effects of therapy and reduction in the risk of congenital deformities for with the onset of pregnancy
PCT/EP2008/006253 WO2009027003A1 (en) 2007-08-24 2008-07-30 Use of gestagens in combination with (6s)-5-methyltetrahydrofolate for the therapy of endometriosis with simultaneous reduction of therapy side effects and the reduction of the risk of congenital malformations in case of pregnancy

Publications (1)

Publication Number Publication Date
ZA201002035B true ZA201002035B (en) 2012-09-26

Family

ID=38846909

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/02035A ZA201002035B (en) 2007-08-24 2010-03-23 Use of gestagens in combination with (6s)-5-methyletrahydrofolate for the thepary of endometriosis with simultaneous reduction of therapy side effects and the reduction of the risk of congenital malformations in case of pregnancy

Country Status (17)

Country Link
EP (2) EP2027855A1 (en)
JP (1) JP2010536808A (en)
KR (1) KR20100047872A (en)
CN (1) CN101784271A (en)
AR (1) AR070023A1 (en)
AU (1) AU2008291406A1 (en)
BR (1) BRPI0815756A2 (en)
CA (1) CA2696030A1 (en)
CL (1) CL2008002485A1 (en)
EA (1) EA201000338A1 (en)
MX (1) MX2010002190A (en)
PA (1) PA8793901A1 (en)
PE (1) PE20090608A1 (en)
TW (1) TW200930377A (en)
UY (1) UY31306A1 (en)
WO (1) WO2009027003A1 (en)
ZA (1) ZA201002035B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101874806A (en) * 2009-04-29 2010-11-03 北京本草天源药物研究院 Dienogest solid preparation
CN108379226B (en) * 2018-05-28 2019-11-29 上海市计划生育科学研究所 Chlormadinone self-emulsion composition, preparation method and application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH693255A5 (en) 1997-06-13 2003-05-15 Eprova Ag Use of tetrahydrofolates natürlichenstereoisomeren in the form suitable for the preparation of a pharmaceutical composition for influencing the homocysteine ​​level.
JP4418105B2 (en) 1997-12-26 2010-02-17 持田製薬株式会社 Angiogenesis inhibitors containing dienogest as an active ingredient
CH693905A5 (en) 1999-04-15 2004-04-15 Eprova Ag Stable crystalline salts of 5-methyl tetrahydrofolic acid.
US20050032741A1 (en) * 2003-08-06 2005-02-10 Balaji Venkataraman Vitamin Compositions
DE102005034498A1 (en) * 2005-07-20 2007-01-25 Grünenthal GmbH Oral contraception with Trimegeston
DE102005053771A1 (en) * 2005-11-09 2007-05-10 Grünenthal GmbH Dosage form for hormonal contraception

Also Published As

Publication number Publication date
PA8793901A1 (en) 2009-04-23
WO2009027003A1 (en) 2009-03-05
JP2010536808A (en) 2010-12-02
KR20100047872A (en) 2010-05-10
EP2027855A1 (en) 2009-02-25
AR070023A1 (en) 2010-03-10
BRPI0815756A2 (en) 2015-02-18
TW200930377A (en) 2009-07-16
CA2696030A1 (en) 2009-03-05
UY31306A1 (en) 2008-11-28
AU2008291406A1 (en) 2009-03-05
MX2010002190A (en) 2010-03-17
EA201000338A1 (en) 2010-08-30
EP2194978A1 (en) 2010-06-16
PE20090608A1 (en) 2009-06-12
CL2008002485A1 (en) 2009-11-20
CN101784271A (en) 2010-07-21

Similar Documents

Publication Publication Date Title
EP2129618A4 (en) System for the preparation and distribution of beverages in a transportation unit
HRP20160689T1 (en) Selective progesterone modulators in the treatment of uterine bleeding
IL244103A0 (en) Controlled release corticosteroid compositions and their use in the treatment of otic disorders
GB2443823B (en) Devices and methods for use in construction
PT2162118T (en) Porous microspheres and their use in therapy
EP2355731A4 (en) Fixation plate for use in the lapidus approach
IL198200A0 (en) Use of estradiol valerate or 17??-estradiol in combination with dienogest for oral therapy for maintaining and/or increasing the female libido
ZA200905467B (en) Method for activation of helper T cell and composition for use in the method
EP2210583A4 (en) Gel sheet and cosmetic preparation in sheet form using the same
PL1839182T3 (en) Use of configurations in device with multiple configurations
GB0720092D0 (en) Improvements in bus stops and bus shelters
IL206690A0 (en) Protein kinase inhibitors and their use in the preparation of medicaments
HK1204626A1 (en) Use of cd83 in combination therapies cd83
IL212672A (en) Cycloundecadepsipeptide compounds and use of said compounds in the manufacture of medicaments
EP1960526A4 (en) Plasmids and packaging cell lines for use in phage display
GB0613840D0 (en) Methods and products for in vitro genotyping
ZA201002035B (en) Use of gestagens in combination with (6s)-5-methyletrahydrofolate for the thepary of endometriosis with simultaneous reduction of therapy side effects and the reduction of the risk of congenital malformations in case of pregnancy
GB201020621D0 (en) Pin for hygienic and/or medical use in the anal region
GB0703683D0 (en) The treatment of complications in pregnancy
PL2288342T3 (en) Magnesium system and use thereof in the cosmetics industry
GB2453024B (en) Method for reducing the risk of tilting in vehicles
PL366675A1 (en) Shapes for use in lighting fittings and for construction purposes
GB0819103D0 (en) Raphaine compounds and their use in therapy
PL382896A1 (en) The manner and system for taking of measurements in electroimpedence tomography
GB0714490D0 (en) Recreational and theraputic products